THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
Title Are the 90s the New 80s ? TAVR in
Name Nonagenarians
: Text Michael Mack , MD : “ We know overall outcomes of TAVR are good , but it ’ s appropriate to look at a number of subgroups of patients . One of those groups of patients was 90 years old or older . We wanted to know whether it was appropriate to use this very expensive medical technology and put these elderly patients through a procedure if we ’ re not benefiting them either in terms of quality of life or life longevity .”
Title Thanks LVAD : Mended Hearts Name Wants : Text Patient LVAD Stories Michele Packard-Milam : “ What we ’ re really hoping to do is help people see LVAD as not just a bridge to heart transplant , but it ’ s also , possibly now , a destination therapy . […] It ’ s not just 10 more years . It ’ s 10 more good years — and 10 years and counting .”
Title LEADERS-FREE : The First Name Randomized : Text Clinical Trial Dedicated to PCI in High-bleeding Risk Patients Philip Urban , MD : “[ The BioFreedom™ drugcoated stent ] is stainless steel ; it ’ s got an abluminal surface ; it ’ s been treated in such a way that it ’ s capable of retaining the drug without the use of a polymer or a carrier . Therefore , the drug moves into the vessel wall quite rapidly . Over a period of 4 weeks , it ’ s all done . […] We knew that some patients , systematically excluded from trials , simply can ’ t take 6 months or 12 months .”
Date Source
Date Source
Date Source
Title TAVR : Good Results Confirmed for Name New-generation : Text TAVR Devices Alec Vahanian , MD : “[ The Lotus TM Valve ] is one of the new devices . It has several particular advantages : it can be repositioned ; it can be retrieved for more satisfactory positioning ; and it also has a skirt , which is aiming at decreasing the paravalvular leaks . So there are plenty of theoretical — and , point of fact , real — advantages . What we didn ’ t know was the long-term or mid-term follow-up .”
Title A Universal Antidote to Reverse Name the Anticoagulant : Text Effects of Factor Xa Inhibitors Mark Crowther , MD : “ It is super important to have a universal antidote because inhibitors are becoming more and more frequently used in clinical practice . They have really changed the approach to anticoagulation for patients at high risk of blood clots , including patients with atrial fibrillation and deep vein thrombosis .”
Title PEAGASUS Long-term Results : Name Ticagrelor : Text in Patients with Prior-MI Steve Zelenkofske , DO : “ The patients who stayed on the Brilinta therapy , they continued to show a benefit . There was a 21 % reduction compared to those who continued the therapy . So there is a benefit for staying on and maintaining therapy in those patients .”
Date Source
Date Source
Date Source
10 CardioSource WorldNews : Interventions May / June 2016